Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Psoriasis Market Outlook
Thelansis’s “Psoriasis Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Psoriasis treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Psoriasis
Overview
Psoriasis,
affecting approximately 2-3% of the global population, is primarily an
inflammatory skin condition characterized by abnormal epidermal differentiation
and hyperproliferation. The disease’s pathophysiology involves the activation
and migration of T-cells to the dermis, leading to the release of cytokines,
particularly tumor necrosis factor-alpha (TNF-alpha), which induces
inflammation and accelerated skin cell production. This condition manifests
with various symptoms, including dry, thick, raised patches on the skin covered
by a silvery-white scale. These patches often provoke itching, especially in
specific areas like the scalp, lower legs, and groin. In cases where psoriasis
affects the hands and feet, painful fissures and cracks may develop, impairing
manual tasks and walking. Severe psoriasis on the body can also lead to painful
fissures and bleeding. Psoriasis is the most common autoimmune disease
attributed to an inappropriate activation of the cellular immune system. The
disease’s development hinges on the activation and migration of T cells to the
dermal layer, which triggers cytokine release, instigating inflammation and the
rapid proliferation of skin cells. The precise trigger for T cell activation
remains unknown, but it has long been recognized as a pivotal factor in the
disease’s pathogenesis. Numerous clinical studies involving a range of
immune-modulating biological agents have been conducted to explore the role of
T lymphocytes in psoriasis patients.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment